Evidence map›Paper›PMID 33386947›Full record

Trial reportWorld journal of urology2021

B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis?-A randomized study.

I Glykas, Ch Fragkoulis, D D Mitsikostas, A Papatsoris, I Mitsogiannis, G Papadopoulos, A Skolarikos, I Gkialas, K Ntoumas, A Dellis

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Clinical Utility of βResearch and reports in urology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

I GlykasDepartment of Urology, General Hospital of Athens G. Gennimatas, Athens, Greece. giannis.glykas@gmail.com.ORCID http://orcid.org/0000-0002-0681-8685
Ch FragkoulisDepartment of Urology, General Hospital of Athens G. Gennimatas, Athens, Greece.
D D Mitsikostas1st Department of Neurology, Aiginiteio Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
A Papatsoris2nd Department of Urology, Sismanoglio Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
I Mitsogiannis2nd Department of Urology, Sismanoglio Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
G PapadopoulosDepartment of Urology, General Hospital of Athens G. Gennimatas, Athens, Greece.
A Skolarikos2nd Department of Urology, Sismanoglio Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
I GkialasDepartment of Urology, General Hospital of Athens G. Gennimatas, Athens, Greece.
K NtoumasDepartment of Urology, General Hospital of Athens G. Gennimatas, Athens, Greece.
A Dellis2nd Department of Surgery, Aretaieion Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
General Hospital of Athens G. Genimatas · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION AND

objectiveMultiple sclerosis (MS) is the most frequent autoimmune demyelinating disease of the central nervous system. MS patients usually present with lower urinary tract dysfunction (LUTD). Objective of this study is to evaluate and compare the efficacy and safety of treating MS patients with LUTD with either a b3 agonist (mirabegron) or anticholinergics. The study's primary outcome is the LUTD symptom improvement. MATERIAL AND

methodsThis is a multi-center, single-blinded, comparative study including 91 MS patients with LUTD. At baseline, patients underwent thorough clinical examination, urine cultivation and abdominal ultrasound and completed urination diaries and specific, validated questionnaires (NBSS, MusiQoL). At second visit, patients were administered either mirabegron or anticholinergics. Treatment was always carried out alongside with MS treatment. Reevaluation was performed 3 months after first visit. Patients underwent the same clinical and imaging tests that were carried out at first visit.

resultsWe compared several clinical and imaging parameters between the two groups at first visit and month 3 after treatment. Νo statistical difference was noted between the mirabegron group and the anticholinergic group in terms of LUTD improvement. In both groups, improvement from baseline regarding LUTD was recorded. Statistical analysis was performed using the paired and unpaired t test method. No patient discontinued either medication due to side effects.

conclusionsMS patients receiving either mirabegron or anticholinergic therapy for LUTD showed improvement. Nevertheless, no statistical difference was noted between the two cohorts at 3 months in terms of drug efficacy in all the statistically significant parameters.

Indexed as

AcetanilidesCholinergic AntagonistsLower Urinary Tract SymptomsMultiple SclerosisThiazolesAdrenergic beta-3 Receptor AgonistsDrug MonitoringFemaleHumansMaleMiddle AgedSingle-Blind MethodSymptom AssessmentTreatment OutcomeUltrasonographyAcetanilidesAdrenergic beta-3 Receptor AgonistsCholinergic AntagonistsmirabegronThiazolesAnticholinergicsb3 agonistsLower urinary tract dysfunctionMultiple sclerosis

Identifiers

PMID33386947
OpenAlexW3113438264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.